文献速递心脑血管急症重症综合管理与镇静镇痛

远程缺血适应减少急性缺血性卒中合并急性心肌梗死患者的不良事件:一项随机对照试验

Remote ischemic conditioning reduces adverse events in patients with acute ischemic stroke complicating acute myocardial infarction: a randomized controlled trial.
PubMed 文献 · Crit Care · 2024-01-02
一句话结论急性缺血性卒中合并急性心肌梗死患者接受远程缺血适应治疗2周,3个月时主要不良心脑血管事件和死亡减少、功能独立改善。

这项双盲随机对照试验纳入急性缺血性卒中合并急性心肌梗死的患者,随机分入远程缺血适应(RIC)组和假RIC组,分别接受每日两次RIC或假RIC治疗2周,所有患者均接受标准药物治疗。主要终点为入组后3个月内主要不良心脑血管事件(MACCEs)发生率。最终分析纳入RIC组37例和假RIC组40例完成3个月随访的患者:RIC组11例(29.7%)发生MACCEs,假RIC组21例(52.5%)(HR 0.396;95%CI 0.187-0.838;校正P<0.05);RIC组死亡6例(16.2%),假RIC组15例(37.5%)(校正HR 0.333;95%CI 0.126-0.881;P=0.027);RIC组17例(45.9%)达到功能独立(mRS评分≤2),假RIC组6例(15.0%)(校正OR 12.75;95%CI 2.104-77.21;P=0.006)。作者结论认为,在急性缺血性卒中合并急性心肌梗死患者中,远程缺血适应治疗减少了90天主要不良心脑血管事件并改善了功能结局。

要点

  • 急性缺血性卒中合并急性心肌梗死患者接受每日两次RIC治疗2周,3个月MACCEs发生率29.7%(11/37)vs 假RIC组52.5%(21/40),HR 0.396(95%CI 0.187-0.838),校正P<0.05。
  • RIC组3个月死亡6例(16.2%)vs 假RIC组15例(37.5%),校正HR 0.333(95%CI 0.126-0.881),P=0.027。
  • RIC组3个月功能独立(mRS评分≤2)17例(45.9%)vs 假RIC组6例(15.0%),校正OR 12.75(95%CI 2.104-77.21),P=0.006。
  • RIC和假RIC操作均耐受良好。

适用人群与场景

  • 急性缺血性卒中合并急性心肌梗死的患者,随机分组后接受每日两次RIC或假RIC治疗2周,所有患者均接受标准药物治疗。

处置流程与药物剂量

  • RIC组每日两次接受远程缺血适应治疗,假RIC组每日两次接受假RIC治疗,疗程均为2周;所有患者均接受标准药物治疗。

研究设计与关键结果

  • 双盲随机对照试验,80例受试者随机分组,RIC组37例和假RIC组40例完成3个月随访并纳入最终分析。
  • 主要终点:3个月MACCEs(包括全因死亡、不稳定型心绞痛、急性心肌梗死、急性缺血性卒中和短暂性脑缺血发作)发生率RIC组29.7%(11例)vs 假RIC组52.5%(21例),HR 0.396(95%CI 0.187-0.838),校正P<0.05。
  • 3个月死亡:RIC组16.2%(6例)vs 假RIC组37.5%(15例),校正HR 0.333(95%CI 0.126-0.881),P=0.027。
  • 3个月功能独立(mRS评分≤2):RIC组45.9%(17例)vs 假RIC组15.0%(6例),校正OR 12.75(95%CI 2.104-77.21),P=0.006。
  • RIC和假RIC操作均耐受良好。

证据类型、等级与局限

  • 证据类型:双盲随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在急性缺血性卒中合并急性心肌梗死患者中,远程缺血适应治疗减少了90天主要不良心脑血管事件并改善了功能结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute ischemic stroke (AIS) complicating an acute myocardial infarction (AMI) is not uncommon, but can severely worsen the clinical prognosis. This study aimed to investigate whether remote ischemic conditioning (RIC) could provide clinical benefits to patients with AIS complicating AMI.

METHODS: Subjects with AIS complicating AMI were recruited in this double-blind, randomized, controlled trial; assigned to the RIC and sham groups; and respectively underwent twice daily RIC and sham RIC for 2 weeks. All subjects received standard medical therapy. The primary endpoint was the rate of major adverse cardiac and cerebrovascular events (MACCEs) within 3 months after enrollment. MACCEs comprise of death from all causes, unstable anginas, AMI, acute ischemic strokes, and transient ischemic attacks.

RESULTS: Eighty subjects were randomly assigned; 37 patients in the RIC group and 40 patients in the sham-RIC group completed the 3-month follow-up and were included in the final analysis. Both RIC and sham RIC procedures were well tolerated. At 3-month follow-up, 11 subjects (29.7%) in the RIC group experienced MACCEs compared to 21 (52.5%) in the sham group (hazard ratio [HR], 0.396; 95% confidence interval, 0.187-0.838; adjusted p < 0.05). Six subjects (16.2%) in the RIC group had died at the 3-month follow up, significantly lower than the 15 (37.5%) deaths in the sham group (adjusted HR 0.333; 95% CI 0.126-0.881; p = 0.027). Seventeen subjects (45.9%) in the RIC group and 6 subjects (15.0%) in the sham group achieved functional independence (mRS score ≤ 2) at 3-month follow-up (adjusted OR 12.75; 95% CI 2.104-77.21; p = 0.006).

CONCLUSIONS: Among patients with acute ischemic stroke complicating acute myocardial infarction, treatment with remote ischemic conditioning decreased the major adverse cardiac and cerebrovascular events and improved functional outcomes at 90 days.

TRIAL REGISTRATION: URL: www.

CLINICALTRIALS: gov . Unique identifier: NCT03868007. Registered 8 March 2019.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Li S, Xing X, Wang L, et al. Remote ischemic conditioning reduces adverse events in patients with acute ischemic stroke complicating acute myocardial infarction: a randomized controlled trial. Crit Care. 2024. PMID: 38167175. doi:10.1186/s13054-023-04786-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。